Home›Research

GLP-1 research and evidence

Every major GLP-1 trial produces data worth understanding on its own terms, separate from what it means for your coverage or your bill. This desk tracks the registration trials, the cardiovascular and organ-protection outcomes, and the head-to-head comparisons, so the clinical record stays readable next to the commercial one.

The cheapest program on the chart is Collective: compounded semaglutide from $76 a month, with the $199 yearly membership averaged in (Details). SnagRx starts at $99 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →
Flagship data resources: GLP Chart Price Index tracks the real cash-pay price of every US GLP-1 telehealth program, checked every Monday, with 12 months of price history. Our study on the gap between advertised and real GLP-1 prices measures how far the advertised figure runs below the real cost. Our newest study on compounded vs. branded GLP-1 cash prices measures the drug-by-drug cost gap between the two pathways, with a downloadable dataset. Our oral vs. injectable GLP-1 comparison covers what the 2026 Wegovy pill approval changes about cost and convenience.
Efficacy, 4 min read
Zepbound for MASH and fatty liver: what the SYNERGY-NASH data really shows
Tirzepatide resolved MASH in up to 62% of patients in SYNERGY-NASH, the biggest effect any drug has shown. Zepbound still has no MASH approval. Wegovy got one in June 2026.
Efficacy, 4 min read
Zepbound for HFpEF: what SUMMIT showed and who writes the prescription
The SUMMIT trial showed tirzepatide cut the combined rate of cardiovascular death and worsening heart-failure events by 38 percent in patients with HFpEF and obesity. The Zepbound label never followed, so prescribing it for heart failure is off-label and coverage still runs through obesity or sleep apnea.
Efficacy, 5 min read
Tirzepatide vs semaglutide: the head-to-head result and what each costs
One trial put the two molecules against each other in people with obesity and no diabetes. Tirzepatide took off 20.2 percent of body weight at 72 weeks and semaglutide 13.7 percent.

Two cash programs to check.

No insurance needed.

  1. SnagRx$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
  2. Medvi$299 a monthFirst month $179compounded semaglutideCheck price →Straight to MEDVi's GLP-1 sign-up
Written and edited by GLP ChartAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program, and payment never changes a score. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.